Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9391225 | 0.96 | ERAP2 (0.49) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL30309257 | 0.93 | LNPEP (0.52) | ERAP2LNPEPECE1SLC15A2PSMB1 | |
| SCHEMBL29961451 | 0.92 | ERAP2 (0.47) | ERAP2LNPEPGNPATOPRK1SLC15A2 | |
| SCHEMBL29531327 | 0.92 | ERAP2 (0.47) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL9747696 | 0.92 | ERAP2 (0.47) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL9747710 | 0.92 | ERAP2 (0.47) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL31453801 | 0.92 | SLC15A2 (0.51) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL29849009 | 0.92 | SLC15A2 (0.51) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL30806109 | 0.92 | GHSR (0.46) | ERAP2LNPEPGNPATECE1OPRK1 | |
| SCHEMBL5970308 | 0.92 | GHSR (0.47) | ERAP2LNPEPOPRK1GHSRPSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | ERAP2 1179/4885LNPEP 1120/4885GNPAT 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.